HIL at JP Morgan Healthcare Conference – the CICC Israel Lounge

HIL at JP Morgan Healthcare Conference – the CICC Israel Lounge   HIL will partake in the CICC’s Israel Lounge, on January 13-14th, during the JP Morgan Healthcare conference. Come and meet 1×1 with our CEO Sagi Brink-Danan, to get the latest on our achievements to date, plans for the future, and financing activities. Email us to set […]

HIL awarded €2.5M in grant funding by the EU

HIL awarded €2.5M in grant funding by the EU The European Commission managing Horizon 2020 – the EU Framework Programme for Research and Innovation – today approved HIL’s Phase-II proposal, at a total budget of €3.3M. The positive funding decision, under Horizon 2020 SME instrument, followed an extensive review process, culminating in an in-person pitch […]

Dr. Ehud (Udi) Netzer joins HIL’s Board of Directors

Dr. Ehud (Udi) Netzer joins HIL’s Board of Directors Dr. Netzer is a seasoned technology leader with over 35 years of experience covering all phases of basic research, product development, engineering, commercialization and senior management. During the past 15 years Dr. Netzer served as CEO of Orbit Systems, Head of R&D of the Israel Atomic […]

HIL and CERN enter collaboration (and Globes coverage)

HIL and CERN announce collaboration (and Globes coverage) Novel technologies developed at CERN could be used in HIL’s system, helping to further reduce the size and cost of Proton Therapy systems and achieve HIL’s goal of making this important treatment modality accessible to every patient around the world. The new collaboration is supported by a […]

HIL and Hebrew University announce new R&D and manufacturing facility in Jerusalem

HIL and Hebrew University announce new R&D and manufacturing facility in Jerusalem Calcalist, one of Israel’s leading financial news outlets, published HIL’s plan to set up a new R&D and manufacturing center on a 700 square-meter space leased from the Hebrew University in Jerusalem.  HIL will use the new facility to complete the development of […]

HIL recognized in Israel’s Personal Medicine / Longevity industry 2019 report

HIL recognized in Israel’s Personal Medicine / Longevity industry 2019 report HIL is featured as one of 160 companies in the Aging Analytics Agency and Vetek association’s 2019 report on the Longevity Industry in Israel. The report is part of a collaborative project by the Global Longevity Consortium, consisting of the Biogerontology Research Foundation, Deep […]

HIL makes cover of The Marker Bio Magazine on International Women’s Day

HIL makes cover of The Marker Bio Magazine on International Women’s Day HIL is featured in the cover story of The Marker’s Bio Magzine’s special edition for International Women’s Day. The issue is dedicated to the subject of Women’s Health, and emphasizes the importance of HIL’s vision – making Proton Therapy affordable and widely available […]

Dr. Raphaël Van Roermund joins HIL’s R&D team

Dr. Raphaël Van Roermund joins HIL’s R&D team Dr. Van Roermund, holding a PhD in quantum physics, is an expert in proton beam transport, dose delivery systems and dosimetry. Raphael comes to HIL following 8 years at IBA, the world leading company in Proton Therapy, where he managed several R&D projects – including the development […]

HIL to Participate in IIA’s China Roadshow

HIL to Participate in IIA’s China Roadshow HIL was invited to partake in Israel Innovation Authority’s (IIA) and Israeli Export Institution’s delegation to China, in affiliation with CSTEC (China Science and Technology Exchange Center). Following a multi-stage competitive process – culminating in a pitching event to a panel of Chinese investors in Tel Aviv on […]